This February Pacritinib (VONJO) received approval by the FDA as an oral drug for the treatment of intermediate or high-risk primary or secondary myelofibrosis in adults. It is a selective inhibitor of Janus kinase 2 (JAK2) and IRAK1, without inhibiting JAK1.

Pacritinib has a macrocyclic nature, so Chemspace offers you a Macrocyclic Compounds set (21 K) and Macrocyclic Compounds Scaffolds (74 K), which could be the perfect start for your research in anti-cancer medications and others!